immunohistochemical staining. Methods-Biopsy specimens before and after treatment were studied from patients diagnosed as having acute myeloid or lymphoblastic leukaemia. Specimens after treatment encompassed periods from two to 56 weeks from the start of treatment. Routine Haemopoietic regrowth after chemotherapy is usually monitored by sequential examinations of peripheral blood samples. Few studies have investigated the underlying appearances in bone marrow trephine biopsy specimens,12 and little information is available on the sequential changes in the marrow as regrowth occurs. As peripheral blood findings frequently include dysplastic cellular changes which may persist for long periods, it is of interest to know whether these reflect haemopoietic stem cell or stromal cell damage sustained as a result of chemotherapy. The three cases in which AML developed from myelodysplasia (all FAB subtype refractory anaemia with excess blasts (RAEB) at initial presentation) had AML phenotypes of AML-M2, M4, and M6, respectively, by the time frank leukaemia was present. The patient who developed AML-M4 had a transient phase of RAEBt in which more than 50% of blasts were erythroid: he received a single course of DAT 3 + 10 at that time and immediately afterwards had marrow indicators of AML-M4.
CASES OF MINIMAL RESIDUAL DISEASE
In two cases (one AML-M2 and one AML-M4), residual leukaemic blast cells were clearly demonstrated by immunohistochemical staining of specimens (both at three weeks after treatment). In one case (AML-M4) these had not been seen with routine stains and in the other (AML-M2) they had been interpreted as equivocal, considered possibly to be regenerating normal elements.
In the case of AML-M4 expression of calgranulin and CD15 by large mononuclear cells represented a phenotype which characterised the patient's leukaemic blasts before treatment and which is found only in rare group.bmj.com on April 20, 2017 -Published by http://jcp.bmj.com/ Downloaded from had exceptionally prolonged periods (more than three months) of poor haemopoietic function as judged by blood, marrow aspirate, and trephine biopsy findings. One was the patient with recurrent sepsis. The second patient had a diagnosis of AUL, subsequently revised to ALL, and her disease responded poorly to both AML and ALL therapeutic regimens; her first normocellular biopsy specimen was obtained 27 weeks after starting treatment. The third patient was a 54 year old man with AML-M4, for whom no readily identifiable cause of poor regrowth was found. His disease subsequently relapsed, after which a marrow biopsy specimen showed good regrowth with normal cellularity by six weeks. He sustained a further relapse, however, after autologous marrow transplantation 17 weeks later. The fourth patient was a 49 year old man who developed hypocellular AML-M2 on a background of myelodysplasia. Despite autologous marrow transplantation he had persistently hypoplastic marrow with prominent megakaryocyte and erythroid dysplasia up to 54 weeks from starting treatment.
Discussion
Haemopoietic regeneration after treatment for acute leukaemia is usually monitored by repeated peripheral blood and bone marrow aspirate analyses. Our results show that there is generally good correlation between the appearances in bone marrow biopsy specimens and those in concurrent blood or aspirated marrow samples over extended periods of time after induction treatment. This finding confirms the validity of blood and aspirate samples for monitoring bone marrow function during and after treatment for acute leukaemia.
A study of biopsy samples, however, offers the opportunity to evaluate aspects of the spatial organisation of haemopoietic cells, which may be of importance in determining the adequacy of reconstitution of normal haemopoietic function. Complex interactions between stromal cells, extracellular matrix molecules, growth factors and haemopoietic progenitor cells are required for normal production of blood cells.'6 Abnormal spatial organisation of the bone marrow may reflect, or be a cause of, failure of this process. For example, spatial as well as cytological disturbances of haemopoietic cells are found in the primary myelodysplastic syndromes and are frequently associated with ineffective haemopoiesis. 17 The use of immunohistochemistry in conjunction with spatial and cytological analysis of marrow biopsy specimens permits clear demonstration of the lineages and stages of maturation of the cells present.' '1
Because of the retrospective nature of our study, the number and timing of biopsy samples from different patients were variable so that direct comparisons could not be made between all individuals. In keeping with previous studies, however,' 2 our results show that profound disturbances of haemopoiesis occur after treatment for AML and ALL. The availability of serial biopsy specimens from our patients allowed us to demonstrate wide variation in the speed and sequence of haemopoietic regeneration. Relatively early biopsy specimens, taken between three and eight weeks from the start of treatment, showed the existence of a transient phase of hyperplasia in a proportion of patients, the cause of which remains unexplained. Persistent hypoplasia, on the other hand, coexisted in all but one case with a complicated clinical course, albeit for different reasons in each patient.
Dysplastic changes took the form of cytological and spatial abnormalities, predominantly affecting erythroid cells and megakaryocytes. Abnormal paratrabecular distribution of erythrocytes was not necessarily associated with failure of erythroid maturation, indicating that this area of bone marrow stroma, normally occupied by early granulocytes, permits normal erythropoiesis. This suggests that marrow stromal compartmentalisation may be less rigid than cell culture derived models of specific haemopoietic microenvironments would imply.18 In our biopsy specimens repopulation of paratrabecular sites by granulocytes was accompanied by return of erythropoiesis to its more usual sites in the central areas of marrow spaces, possibly due to simple physical displacement.
The appearance of synchronous erythroid colonies in specimens taken after treatment may reflect the development of new colonies in a marrow which has been suddenly and severely depleted of the normal mixture of cells at different maturation stages. It is a feature seen in some cases of primary myelodysplasia"7 and could be the result of subtle abnormalities of interactions between stroma and developing erythroid cells. The megaloblast-like changes seen in some biopsy specimens also resembled those found in some cases to see whether mast cell numbers were associated with poor regrowth in the context of acute leukaemias. High mast cell numbers were found in only two specimens taken after treatment, and showed no association with poor or dysplastic regeneration.
Stromal fibrosis has also been reported to have an adverse effect on haemopoietic recovery after marrow transplantation,26 but there was no delay in regrowth in the one patient of our series in whom fibrosis was present after induction chemotherapy. Nor were persistent abnormalities of spatial organisation or cytological atypia found in this case, suggesting that such fibrosis may be focal or transient and is not necessarily of clinical importance. Some of the cases reported by Wittels' also developed marrow fibrosis without noticeably impaired regrowth.
Our study has also provided data of relevance to the assessment of minimal residual disease in acute leukaemia. In biopsy specimens taken as early as two or three weeks after initial 
